Chen Hui, Yan Jingze, Liu Zeyuan, Ge Xiaolin, Sun Xinchen, Xia Xiaojie
Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Department of Radiation Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211199, China.
Curr Oncol. 2025 Mar 24;32(4):189. doi: 10.3390/curroncol32040189.
This study aims to evaluate the clinical effectiveness of trilaciclib in preventing myelosuppression in patients with esophageal cancer undergoing chemotherapy. Based on the use of trilaciclib, 81 patients were divided into a primary prevention group (PP group, n = 49) and a secondary prevention group (SP group, n = 32). The incidence of myelosuppression, antibiotic usage rate, survival outcomes, and other treatment-related toxicities were analyzed using chi-square tests and Kaplan-Meier survival curves. The incidence of chemotherapy-induced myelosuppression in the SP group was significantly higher than that in the PP group (96.9% vs. 79.6%), with a significantly higher proportion of grade III and above events (37.6% vs. 8.2%, < 0.05). For chemotherapy-induced neutropenia, the incidence of grade III/IV events in the SP group was significantly higher than in the PP group (28.1% vs. 8.2%, = 0.017). Additionally, the SP group experienced higher rates and severity of chemotherapy-induced anemia and thrombocytopenia. The PP group provided better protection against grade III/IV leukopenia and neutropenia ( < 0.05). Non-hematological toxicities and efficacy outcomes were similar between groups ( > 0.05). The study is the first to demonstrate that trilaciclib is a safe and effective option for the prevention of myelosuppression in esophageal cancer patients.
本研究旨在评估曲拉西利在预防接受化疗的食管癌患者骨髓抑制方面的临床疗效。基于曲拉西利的使用情况，81例患者被分为一级预防组（PP组，n = 49）和二级预防组（SP组，n = 32）。使用卡方检验和Kaplan-Meier生存曲线分析骨髓抑制的发生率、抗生素使用率、生存结局及其他治疗相关毒性。SP组化疗诱导的骨髓抑制发生率显著高于PP组（96.9%对79.6%），III级及以上事件的比例显著更高（37.6%对8.2%，P<0.05）。对于化疗诱导的中性粒细胞减少，SP组III/IV级事件的发生率显著高于PP组（28.1%对8.2%，P = 0.017）。此外，SP组化疗诱导的贫血和血小板减少的发生率及严重程度更高。PP组对III/IV级白细胞减少和中性粒细胞减少提供了更好的保护（P<0.05）。两组间非血液学毒性和疗效结果相似（P>0.05）。该研究首次证明曲拉西利是预防食管癌患者骨髓抑制的一种安全有效的选择。
